90
+
products
7
therapeutic areas of focus
600
+
employees
OUR HISTORY

From our humble beginnings

We started with an unsurpassed commitment to help patients tackle their health needs with fresh thinking and novel solutions.

February 2022

Avion Pharmaceuticals announces the FDA approval and availability of Dhivy® for the treatment of Parkinson’s disease.

2021

Alora acquires Osmotica Pharmaceuticals (Marietta, GA) to bolster its platform of generic and branded product lines and contribute to the long-term growth of contract research and development and manufacturing capabilities.


FDA approval of DHIVY®, a unique carbidopa/levodopa combination product for the treatment of Parkinson’s disease.

2019

Alora acquires Sovereign Pharmaceuticals (Fort Worth, TX). The acquisition expands our product portfolio while integrating manufacturing capabilities with a CMO we already did business with. During that year Alora also expands Sovereign’s CMO footprint, capabilities, and production volume.

2018

Avion Pharmaceuticals announces approval of the first New Drug Application (NDA) in the oral contraceptive category.

2017

Alora acquires and launches a hypothyroidism product and endocrinology sales force. This product was originally developed and launched in 2009.

October 2016

Acella Pharmaceuticals, LLC, announces approval of a generic Bromfed®, an antihistamine, decongestant, and cough suppressant.

2016

Art Deas is announced as CEO of Alora Pharmaceuticals, the parent company of six specialty pharmaceutical and manufacturing companies.

2012

The Prenate® Vitamin Family, a branded prenatal vitamin line is launched.

2007-2010

Alora establishes a successful track record of commercializing products.

2007

Alora Pharmaceuticals is founded.

“The foundation that makes our company so successful is that we are equally as passionate about our workforce and company culture as we are investing in our communities and providing best-in-class product offerings.”

OUR LEADERSHIP

We are uncommon people doing extraordinary things.

At Alora Pharmaceuticals, we strive to make a real-world difference in the lives of patients. Our leadership team brings together a wealth of education and experience, coupled with an unrivaled commitment to pursue new and innovative opportunities with an eye on helping people live healthier lives.

OUR AWARDS

We are always upping our game.

At our core, we have an entrepreneurial spirit. Alora Pharmaceuticals and our entire family of companies make real differences in the lives of patients by challenging the status quo with new ideas. Over the years, we have received numerous industry awards and recognition because of this steadfast drive to succeed.

Awards & Recognition
  • 2022: Alora Pharmaceuticals Wins Top Pharmaceutical Award – Best of the Best in Healthcare Marketing Honored at Event in NYC on September 23rd
  • 2020: Healthcare & Pharmaceutical Awards 2020 – Avion is “the most innovative women’s health pharmaceutical company in the USA”
  • 2020 & 2021 & 2022: Avion and Acella Awarded Best Places to Work in Medical Sales
  • 2014: Avion Pharmaceuticals, LLC, Awarded HDMA Diana Manufacturer Award

BROMFED® is a registered trademark of Wockhardt.

Harold Deas

Chief Executive Officer

Harold A. Deas, also known as Art, has been the Chief Executive Officer of Alora Pharmaceuticals, LLC, since February 3, 2016, and served as its Chief Operating Officer until February 3, 2016.

Art has more than 25 years of pharmaceutical experience, initiating his pharmaceutical career with Marion Laboratories. Since then, he served as Vice President of Marketing and Sales at Alliant Pharmaceuticals, Inc. He has also served positions of progressive leadership and responsibility within the pharmaceutical and biotech industry including: sales, institutional sales, marketing, clinical research, professional education, new product marketing, district manager, regional manager, and division sales manager for companies such as Genentech and Aventis.

The significant contributions Art has made throughout his career in the pharmaceutical industry provide the necessary framework for future growth and sustainability. He has been instrumental in helping Alora build a successful portfolio of generic and specialty niche pharmaceutical drug and medical device products. Art continuously drives expansion while identifying strategic opportunities within the markets that are essential to the company’s business.

He holds a Bachelor of Science in Biology from the University of South Carolina and an MBA in International Business from The Edinburgh Business School.

Shannon Faught

Chief Commercial Officer

Shannon Faught is the Chief Commercial Officer for Alora Pharmaceuticals and is responsible for leading the commercial team responsible for all specialty care products that are either in promotion, launch preparation, or in consideration for future commercialization. Shannon’s team will have a critical eye towards maximizing product potential for promoted brands as well as developing standards for launch excellence for future products.

Shannon brings 18 years of commercial leadership experience in the pharmaceutical industry. In her 18 years as a key female leader for Sanofi, she had the opportunity to lead products at all phases of the life cycle including launch, in-line brand management, and generic transition and was a key contributor to the success of Lantus, a multibillion-dollar insulin that set the standard for diabetes injectable treatment. Shannon’s leadership experience spans all the critical aspects of commercialization including sales, marketing, market access, operations, and omni channel strategy.

Shannon holds a Bachelor of Science in Business Administration in Marketing from The Ohio State University.

Ben Burgess

Senior VP Operations, Business Development

Benjamin Burgess is responsible for leading Alora's improvement and growth initiatives. Through internal product development programs, acquisitions, licensing agreements, joint ventures, and strategic alliances, Benjamin directs company portfolio objectives while also designing and implementing plans for company growth and financial profitability. In addition, he has oversight in management of contract manufacturing, packaging, third-party logistics partners, and active pharmaceutical ingredient (API) sourcing.

Prior to joining Alora, Benjamin began his healthcare career as marketing manager in the hospital finance industry, working for Dimension Financial Services in Atlanta. Benjamin joined Alora in 2010 and progressively took on increasing roles of responsibility including supply chain manager, analyst, and director of business development, eventually assuming the role as the senior director.

Benjamin holds a Bachelor of Science in Business Administration from Ashford University and in 2013, he was presented with a Stevie Award.

Srihari Vedartham

Senior VP, Global Commercial Development & Licensing

Srihari Vedartham has more than 15 years of experience with profit and loss responsibility for the business development and product development efforts; a deal sheet of more than 10 transactions (>$700 million) and raising more than $100 million of financing through deal making and new product planning efforts. He has successful specialty drug launch experience, including with Atryn, Xenazine, Sabril, and Onfi. He has demonstrated expertise and success in starting companies from the ground up. His experience includes working in organizations with fewer than 20 employees and more than 6,000 employees worldwide.

Srihari holds a Master’s degree in Organic Chemistry from Osmania University in India and an MBA from Tennessee Tech University.

Scott Lindler

Chief Financial Officer

Scott Lindler joined Alora Pharmaceuticals in 2012 and is responsible for directing all of the organization’s financial activities, including accounting, planning, treasury, and shared services. Scott has more than 20 years of experience in various accounting and finance roles across multiple industries.

Scott has a Bachelor of Science in Accounting from the University of Alabama – Culverhouse School of Business and is a CPA in the state of Georgia. Scott has completed development course work in the Wharton Executive Education program and is a two-time recipient of Acella’s President’s Club award, which recognizes employees whose commitment directly impacted the success of the company.

Allen Fields

Executive VP, Clinical & Regulatory Affairs, Head of Research & Development

Allen Fields is responsible for Clinical, Regulatory and Technical Affairs, Drug Safety Pharmacovigilance, and Research and Development.

Allen has more than 28 years of experience as a clinical and regulatory affairs professional. He has managed IDEs, INDs, MAAs, NDAs, BLAs, ANDAs, SNDAs, 510Ks and PMAs. He has led drug development programs, due diligence, preparation of documents, strategic clinical and regulatory planning, and has had meetings with the global regulatory agencies. His expertise in drug development in all phases of development has led to over 35 approvals. He has held senior clinical and regulatory affairs positions at small and large pharmaceutical firms, including TAP Holdings, Purdue Pharma, Alliant Pharmaceuticals, and Quintiles International.

Allen holds a B.S. in Chemistry from Kansas Wesleyan University; M.Ed./M.S. work at Kansas State University; graduate work at University of Kansas School of Medicine; Neuropharmacology Fellowship; and currently additional graduate work at Johns Hopkins University and Walden University.

Miguel Gomez

Chief Quality Officer

Miguel has over 30 years in the pharmaceutical industry and has demonstrated success in establishing strategic plans and initiatives to ensure continuous product supply, quality, and cost efficiencies across international and multi-cultural networks. Leadership, compliance, customer service, safety, and cost are the key drivers in ensuring that the Global Operations organization provides the highest support and visibility through harmonized metrics and programs.

Miguel has a Bachelor of Pharmaceutical Science from the School of Pharmacy University of Puerto Rico.

Chris Schwab

Executive VP, General Counsel

As Executive Vice President and General Counsel of Alora, Chris Schwab is responsible for all legal matters, from contract negotiation and document management to regulatory and licensing requirements. As a member of the Executive Committee, Chris also assists senior management with strategic initiatives and long-term operational planning. Chris has been an attorney in Atlanta since 2000 representing a wide variety of companies across numerous regulated industries. Prior to joining Alora, Chris was the Vice President, General Counsel, and Chief Operating Officer for Healthy Home Transitions, Inc., a behavioral health startup. Prior to that, Chris served as the Vice President and General Counsel of an international slot machine manufacturer. Chris has also served as a Member at Miller & Martin, PLLC, of Counsel at Hartman Simons and Associate at Dow Lohnes PLLC and Sutherland, Asbill & Brennen (now Eversheds Sutherland).

Chris Diton

Executive VP, Trade & Account Management

Chris Diton leads Alora Pharmaceuticals Trade and Sales Operations team responsible for managing and developing wholesaler, retail, and Group Purchasing Organization (GPO) customer relationships across our Alora portfolio of both brand and generic products. Chris’ team works closely with our internal cross functional teams towards maximizing our customer’s experience for both our current portfolio and new product launches.

Chris brings 10 years of trade, supply chain, and operations leadership experience in the pharmaceutical industry. In his 10 years as a senior leader for Harvard Drug and Osmotica, he had the opportunity to lead Purchasing and Supply Chain for both brand and generic products and was a key contributor to the tremendous growth and eventual successful sale of both companies. Chris’ leadership experience spans across several countries/continents and different industries outside of pharmaceuticals including automotive, building materials, and construction where he has worked in product development, quality, purchasing, sales, and manufacturing.

Chris holds a Bachelor of Arts in Supply Chain Management with an emphasis on Engineering from Michigan State University.

logo